Success Story: Advancing Phytotherapy and Drug Discovery: EB1A Approval in 17 Days for a Pharmaceutical Sciences Researcher
Client’s Testimonial:
“I am very happy to hear that the petition for the O1-A visa was successful, and I sincerely thank everyone on your team for their effort and help in putting this petition together!”
On August 26th, 2026, we received another O1-A (Individuals with Extraordinary Ability or Achievement) approval for a Founding Member of Technical Staff in the Field of Computational Chemistry and Materials Discovery (Approval Notice).
General Field: Computational Chemistry and Materials Discovery
Position at the Time of Case Filing: Founding Member of Technical Staff
Country of Origin: Germany
State of Residence at the Time of Filing: New York
Approval Notice Date: August 26th, 2026
Processing Time: 19 days (Premium Processing Requested)
Case Summary:
With a Ph.D. in pharmaceutical sciences, the client has built a distinguished career investigating how naturally derived compounds can be used to develop safer and more effective therapies for complex diseases. His research centers on phytotherapy and drug discovery, with particular emphasis on identifying plant-based compounds for diabetes treatment while also advancing new therapeutic strategies for cancer, infectious diseases, and cardiometabolic disorders. Recognizing the sustained influence of these contributions, our firm successfully prepared and filed an EB-1A (Alien of Extraordinary Ability) petition, which USCIS approved in just 17 days through Premium Processing.
At the time of filing, the client was conducting pharmaceutical sciences research in the United States, focusing on developing novel therapeutics for diabetes, hypertension, and other cardiometabolic disorders. We demonstrated that his work had achieved influence well beyond his own laboratory. Rather than relying on publication metrics alone, we showed how researchers around the world had incorporated his findings into subsequent investigations, illustrating that his research had become a meaningful foundation for continued advances in pharmaceutical sciences. This independent reliance helped establish that his original contributions carried significance across the field.
The client's scholarly record further reinforced this position. He had authored 116 peer-reviewed journal articles, 44 conference abstracts, and 4 book chapters. His publications had accumulated more than 5,900 citations, reflecting broad recognition by other researchers. However, we emphasized that these numbers mattered because they represented sustained use of his discoveries by independent experts addressing important challenges in drug development and disease treatment, rather than presenting the metrics as accomplishments in isolation.
We also highlighted the confidence the scientific community had placed in the client's expertise through his extensive professional service. He had completed at least 116 peer reviews for scholarly publications and had served in multiple editorial capacities, responsibilities generally reserved for researchers whose technical judgment is trusted by journal editors and fellow scientists. In addition, we documented that his research had attracted competitive funding from major governmental organizations, providing further objective evidence that independent institutions considered his work worthy of significant investment because of its scientific value and potential impact.
Another important component of the petition was expert testimony. We submitted two independent recommendation letters from internationally recognized researchers who had become familiar with the client's work through the scientific literature rather than through personal collaboration. Their assessments helped place the client's accomplishments into the broader context of the field and explained why his research had earned widespread recognition.
Together with the objective evidence documenting the client's research achievements, scholarly influence, publication record, peer-review service, and independent recognition, these expert evaluations presented a compelling picture of sustained international acclaim. We are delighted that USCIS approved this EB-1A petition without any RFE, allowing the client to continue advancing pharmaceutical sciences research in the United States.